Targeting PD-L1 in non-small cell lung cancer using CAR T cells

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors are standard non-small cell lung carcinoma (NSCLC) treatments, but many patients lack response.
• Hyperprogressive disease (HPD) is a concern with PD-1/PD-L1 inhibitors in NSCLC.
• Chimeric antigen receptor (CAR) T cells are effective in blood cancers but not yet established for solid tumors like NSCLC.

Purpose of the Study:

• To construct and evaluate PD-L1-targeted CAR T cells for NSCLC treatment.
• To assess the efficacy of PD-L1-CAR T cells in NSCLC models with varying PD-L1 expression levels.
• To investigate the combined effect of PD-L1-CAR T cells and radiotherapy in NSCLC.

Main Methods:

• Construction of CAR T cells engineered to target PD-L1.
• In vitro and in vivo evaluation of PD-L1-CAR T cell activity against NSCLC cell lines and xenografts.
• Assessment of PD-L1-CAR T cell efficacy in combination with low-dose local radiotherapy.

Main Results:

• PD-L1-CAR T cells demonstrated antigen-specific activation, cytokine release, and cytotoxicity against PD-L1-high NSCLC cells and tumors.
• PD-L1-CAR T cells showed improved efficacy against PD-L1-low NSCLC when combined with radiotherapy.
• The combination therapy overcame limitations of PD-L1-CAR T cells in PD-L1-low tumors.

Conclusions:

• PD-L1-CAR T cells offer a novel therapeutic approach for PD-L1-positive NSCLC.
• Combination therapy with radiotherapy enhances PD-L1-CAR T cell efficacy, particularly in PD-L1-low NSCLC.
• This strategy may benefit NSCLC patients, including those at risk for HPD.